Numans Health Food Holdings Company Limited provided consolidated earnings guidance for the year ended 31 December 2025. For the year, the group expects to record a profit for the year after tax of not more than approximately RMB 6.0 million for fiscal year 2025, as compared to approximately RMB 74.9 million for the year ended 31 December 2024. The Board considers that the expected decrease in profit for the year after tax is primarily attributable to the following factors: (1) a significant decline in revenue due to a general trend of consumption downgrade within the economy of the People's Republic of China (the "PRC"); (2) heightened competition from DHA products manufactured in the PRC; and (3) an impairment loss on its inventories of approximately RMB 19.3 million.